HCW Biologics
HCW Biologics is a clinical-stage company developing transformative immunotherapies to combat cancer and age-related diseases, utilizing its proprietary TOBI™ platform.
Services
HCW Biologics is a clinical-stage company focused on advancing transformative immunotherapies to address inflammaging and extend healthspan. The company provides specialized immunotherapies designed to combat cancer and other age-related diseases. Their research and development efforts utilize the proprietary TOBI™ (Tissue factor-Based fusion) platform to design and discover innovative immunotherapeutic drugs.
Products
HCW Biologics' leading products include HCW9218 and HCW9302. HCW9218, an injectable bifunctional fusion protein, combines a TGF-β receptor and IL-15 to enhance natural killer cells and CD8+ T cell cytotoxicity. This molecule aims to rejuvenate the immune system and is currently undergoing clinical trials for chemo-refractory/chemo-resistant solid tumor cancer indications. HCW9302 is another innovative product, an injectable single-chain IL-2-based fusion protein, targeting autoimmune and age-related diseases. It shows potential to activate Treg cells and reduce inflammation in preclinical studies.
Technology
HCW Biologics utilizes the TOBI™ (Tissue factor-Based fusion) platform for immunotherapeutic drug design and discovery. This proprietary technology has enabled the creation of over 30 molecules that can be administered via subcutaneous injection and employed in adoptive cell therapy approaches. The TOBI™ platform focuses on modifying tissue factors to generate targeted immunotherapies that can address a range of diseases.
Clinical Trials
HCW Biologics is actively conducting clinical trials to evaluate their lead molecule HCW9218. These trials focus on chemo-refractory/chemo-resistant solid tumor cancer indications. Preliminary human data readouts from Phase 1/1b trials show promising results. The company is exploring HCW9218's unique mechanism of action to improve the response rate for checkpoint inhibitors in cancer treatment. Additionally, preclinical studies for HCW9302 indicate its potential efficacy in reducing inflammation-related diseases by deactivating inflammasome pathways.
Collaborations
In 2020, HCW Biologics signed an out-license agreement with Wugen Inc. This agreement grants Wugen a worldwide exclusive license with limited rights to develop cell-based therapies for cancer treatments using HCW9201 and HCW9206. This collaboration underscores HCW Biologics' commitment to leveraging partnerships to advance the development of effective cancer therapies.